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Abstract 
In the fight against cancer, new and more specific targets are needed. Here, we offer an example of a potential target that has not been 
widely studied, namely the syncytin protein. Syncytin is expressed mainly in the human placenta and is implicated in placental 
syncytiotrophoblast cell fusion. Not much is known about the role of syncytin in cancer, but the existing data call for more intense 
research. Its retroviral origin and particular tissue distribution make syncytin an interesting potential target in cancer therapy.
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Translational relevance 
This paper reviews an unexplored potential new target in cancer 
therapy. We consider the origin of syncytin, its normal role in 
human placentogenesis and data regarding its relevance in 
cell–cell fusion. Given its particular distribution in normal human 
tissues and its potential roll as an immune modulator and in 
amino acid transport, tissue tolerance and protection against 
retroviral infection, syncytin could be a potential target for 
immune therapy using specific inhibitors. Current data about the 
role of syncytin in cancer are also discussed. 
 
Introduction 
Transposable elements (TEs) or mobile elements are genetic 
components that can have a significant effect on the host 
genome [1,2]. Furthermore, these elements form the majority of 
the human genome. Insertions of TEs influence the 
transcriptional regulation of some genes as well as the 
termination of transcription. Hundreds of examples have been 
identified in which individual exons possess sequences that are 
similar or identical to TE fragments [3,4]. In many of these 
cases, a single exon is involved, and its transcription yields a 
variant mRNA [5]. It has been suggested that TEs are a source 
of variation as a result of the insertion of fragments of their 
sequence into functioning genes elsewhere in the genome. 
One of the potential effects of TEs is the generation of new 
gene sequences [3,6,7] such as the envelope (env) genes of 
retroviral origin found in several mammals. In particular, the 
human genome contains full-length copies of four env open-
reading frames (ORFs) that are highly expressed in the 
placenta [8–10]. 
The best known of the human env-derived genes is syncytin-1, 
or ERVWE1, which originated from a human endogenous 
retrovirus (HERV) of the HERV-W family inserted on 
chromosome 7q21 in human-pre-hominoids 40–45 million years 
ago [11,10]. The env gene maintained an ORF coding for a 538-
amino acid polypeptide that has all the characteristic features of 
env proteins and mediates intercellular fusion in vitro [11–13]. 
Recently, a molecular evolution study of the HERV-W provirus 
in several ape species and 24 humans demonstrated the 
conservation of syncytin-1, as well as its retention of receptor-
mediated fusogenic activity [14]. However, an analysis of the 
synonymous and non-synonymous substitutions indicated a
relatively high degree of amino acid change in hominoids [15], 
which could be consistent with a low degree of selective 
pressure. HERV-W invasion of the primate genome has been 
documented as occurring before the divergence of hominoids 
and Old World monkeys [16,17] and as being inactive [18]. 
Another syncytin, syncytin-2, has also been identified; it is 
functional in all primates, including New World monkeys, but it is 
absent from prosimians, thus dating its entry into the primate 
genome to about 40 million years ago [19,20]. The syncytin-2 
gene encodes a 529-kDa polypeptide with a general 
organization similar to that of retroviral envelopes: a cleavage 
site separates the surface subunit that binds a still unidentified 
receptor on the target cell from the transmembrane subunit 
(TM), which is classically thought to be involved in the fusion 
process [21]. The TM subunit harbours an N-terminal fusion 
peptide, an ectodomain with a leucine zipper motif, a highly 
hydrophobic transmembrane anchor and a C-terminal 
intracellular domain. 
The ectodomains of retroviral envelopes are believed to play a 
pivotal role in their fusogenic function. Indeed, by analogy with 
the pre-fusion and post-fusion structures of influenza 
haemagglutinin, they include a short loop that undergoes a 
dramatic change in geometry during the fusion process [22,23] 
switching the ectodomain from an entirely a-helical to a helix-
turn-helix conformation. When the structure of the syncytin-2 
central domain is compared to that of present-day retroviruses, 
such as MoMLV and the human T-cell lymphotropic virus 
(HTLV-I), the geometries of the pivotal loops of all three 
ectodomains appear virtually identical, despite completely 
different amino acid sequences [24]. 
 
Functions of syncytin 
The HERV-derived syncytin may have played a role in the 
evolution of the human placenta due to its niche function in 
human placentogenesis, albeit in a highly specific manner, as 
the placentas of different mammalian species exhibit structural 
discrepancies [25]. 
Because of its interaction with a specific receptor known to 
function as a retrovirus receptor and an amino acid transporter, 
and its stimulation of cell–cell fusion processes, the protein was 
designated as syncytin (Figure 1). 
The syncytin receptor, or at least the first known functional 
syncytin-binding site, is the sodium-dependent neutral amino
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Figure 1: Potential functions of syncytin—targeting syncitin. 
acid transporter ASCT2, which transports alanine, serine and 
cysteine. Elevated syncytin expression is followed by further cell 
differentiation and generation of the syncytium, formation of gap 
junctions and an increase in β-hCG secretion [26]. The effects 
of syncytin can be blocked in vitro by antibodies directed 
against syncytin or by the use of syncytin antisense strategies 
[11,26]. In addition to in vitro studies, it was recently 
demonstrated that the syncytin locus is strongly preserved in a 
large cohort of individuals, including long-terminal repeat (LTR) 
elements involved in the regulation of gene transcription [14]. 
Apart from these findings, orthologous syncytin loci have been 
identified in the genomes of great apes [14]; moreover, 
expression of syncytin has been described in the rhesus 
monkey endometrium, where it may play a role in 
decasualization or receptivity [27]. 
ASCT2 expression has been demonstrated predominantly at 
the basal membrane of the human syncytiotrophoblast [28–31], 
which may function as the interaction site between syncytin and 
its receptor. The observation that syncytin and ASCT2 levels 
are inversely correlated during cell syncytialization could be 
partially explained by the phenomenon that retroviruses may 
induce down-regulation of their receptors [32]. This can be 
observed after infection of cells with wild-type viruses of the 
type-D interference group, which impairs neutral amino acid 
transport [33]. 
It has been previously reported that an alteration in particular 
placental amino acid transporters is associated with intrauterine 
growth restriction (IUGR) and distinctive anthropometric 
features in the foetus, especially for system A, which transports 
neutral amino acids [34–36]. 
System A, in contrast to the ASCT2 transporter, is down-
regulated in the case of oxygen deficiency and up-regulated in 
the case of excess oxygen [28], which may contribute to foetal 
IUGR. Other transport systems, for example those for arginine, 
have been mentioned in the context of pre-eclamptic placentas 
[37]. 
Another important point concerning syncytin is its potential role 
in maternal immune tolerance to the foetus. Exogenous 
retroviral envelope proteins can inhibit the immune responses of 
leukocytes by means of a highly consistent amino acid 
sequence [38]. This sequence in the syncytin protein may 
therefore contribute to a specific immune modulating 
mechanism within the developing placenta [11]. The nature of 
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additional interactions with other mechanisms such as the MHC 
class I molecules, in particular, HLA-G, which is thought to 
produce immune tolerance [39], or immunoregulatory cytokines 
such as immunosuppressive interleukin-10 [40] remains 
unclear, although syncytiotrophoblast formation stimulated by 
syncytin may subsequently ensure syncytiotrophoblast survival 
via additional interactions with immune or apoptotic 
mechanisms. Whether, or to what extent, syncytin contributes to 
maternal immune tolerance of the foetus or interacts with other 
mechanisms such as apoptotic events at the maternal–foetal 
interface is currently unclear. 
Syncytin expression has been shown to cause cellular 
resistance to infection by spleen necrosis virus [41], and it is 
likely to prevent infection by other retroviruses of the same 
family. It is thus feasible that expression of syncytin by the 
syncytiotrophoblast prevents vertical transmission of a number 
of retroviruses through the placenta. 
 
Gene promoter: description, mutations and 
repercussions. Fusion in cell lines 
The major transcription initiation site of syncytin-1 gene is 56 
base pairs (bp) downstream from a putative CCAAT box [42]. 
Deletion analysis performed on the 59-bp flanking region of the 
syncytin gene indicated that the proximal 148 bp are essential 
for minimal promoter activity and that specific regions of the 
promoter from nucleotides (nts) −1519 to −984 and nts −294 to 
−148 are required for maximal expression in normal trophoblast 
cells. DNAse-I footprint analysis of the region between nts −252 
and +110 revealed three protected regions, FP1–FP3. 
Mutagenesis of a hepatocyte-specific nuclear protein-1-binding 
site in FP1 and a TATA box in FP3 had no effect on basal 
promoter activity. On the other hand, mutation of the CCAAT 
motif and the octamer protein binding site in FP2 decreased 
promoter activity by 88% and 76%, respectively. Mutation of the 
ecdysone receptor response element in FP2, which may bind a 
nuclear hormone receptor, increased basal promoter activity. 
Gel shift and supershift assays indicated that the CCAAT-
binding factor binds to the CCAAT motif and that octamer binds 
to the octamer-binding site. Thus, it can been deduced that the 
syncytin promoter is located in the 59-bp-long terminal repeat of 
the HERV-W gene and that binding sites for GATA and Oct in 
the proximal promoter are critical for transcriptional regulation of 
syncytin in trophoblast cells [42]. 
The 146-bp stretch of the 59-bp flanking region in the human 
syncytin gene from nts 294 to 148 is essential for basal gene 
expression in human BeWo and JEG3 choriocarcinoma cell 
lines, but not in hepatoblastoma and kidney cell lines. Ligation 
of the 146-bp fragment to an SV40 (Simian Virus 40) promoter 
or a human β-globin minimal promoter markedly enhanced 
promoter activity in placental cells, but not in liver or kidney 
cells. DNase-I footprint assays indicated that nuclear extracts 
from BeWo cells, but not HepG2 cells, protected four regions 
(FP1–FP4) of the 146-bp fragment. Furthermore, site-directed 
mutagenesis of an SP1-binding site in FP3 and a GATA-binding 
site in FP4 significantly repressed promoter activity in the 
placental cells. Over-expression of SP1 (Sp1 transcription 
factor), GATA2 (GATA binding protein 2) and GATA3 induced 
syncytin promoter activity but had little or no effect on the 
activity of syncytin promoter fragments containing mutations in 
the SP1- and GATA-binding sites. In addition, GATA2 and 
GATA3 mRNA levels markedly increased during spontaneous in 
vitro differentiation of human cytotrophoblast cells after they 
fused to form a syncytium. These findings suggest that the 146-
bp region of the 59-bp flanking region (nts 2294/2148) of the 
human syncytin gene acts as a placenta-specific enhancer. 
Furthermore, binding of SP1 and GATA family members to this 
enhancer is critical for cell-specific expression of the syncytin 
gene [43]. 
 
Fusion in cancer cells 
Mortensen et al [44] found that human breast cancer cells fused 
with endothelial cells in culture. Expression of syncytin-1 protein 
has also been observed in breast cancer cell lines [45], and 
both tumour cells and endothelial cells express the syncytin-1 
receptor ASCT-2. Using syncytin-1 antisense oligonucleotides 
to down-regulate syncytin-1 expression inhibited breast cancer-
endothelial cell fusion. In addition, the syncytin-1 CHR peptide 
also inhibited cell fusion [45]. Neither the antisense nor the CHR 
peptide experiments, however, effected total inhibition of 
cancer-endothelial cell fusion. It is possible that the antisense 
oligonucleotides did not completely eliminate syncytin-1 
expression. On the other hand, syncytin-2 protein expression 
has also been documented and could contribute to cancer–host 
cell fusion. Further experiments using shRNA-directed down-
regulation of both syncytin-1 and -2 proteins, as well as 
additional putative fusogenic retroviral sequences, are 
underway to test this possibility [46]. 
These data provide strong evidence that syncytin-1 protein is 
involved in mediating cancer-endothelial cell fusion in vitro. 
The involvement of syncytin-1 in tumour cell fusion events was 
subsequently confirmed by Strick et al [47] in endometrial 
carcinomas. In their study, down-regulation of synctytin-1 
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protein expression also inhibited fusion between endometrial 
tumour cells. In agreement with findings in placental cells, both 
cAMP-elevating agents and oestrogens up-regulated syncytin-1 
protein expression; however, only cAMP-elevating agents 
stimulated cell fusion [48]. This apparent discrepancy could be 
ascribed to the fact that oestrogen treatment up-regulates TGF 
beta, which interferes with syncytin-induced fusion. Indeed, 
oestrogen did stimulate cell fusion if TGF beta was neutralized 
with antibodies. Conversely, addition of TGF beta 1 or 3 
reduced the cell fusion induced by cAMP-elevating agents. This 
effect was observed in both endometrial carcinoma cells and 
trophoblast-derived cells. These results show that both cAMP 
and oestrogens may positively regulate syncytin-1 protein 
expression in tumour cells and that TGF beta family members 
may negatively regulate the fusogenic effects of syncytin-1 in 
both trophoblasts and cancer cells [48]. The role of syncytin-1 
and cell fusion in cancer requires further study. 
Published data show that the syncytin-1 protein is not the only 
fusogenic protein expressed by breast cancer cells, and the 
results presented by Strick et al [47] show that additional 
regulators, such as TGF beta isoforms, may be important 
modulators of cell fusion. 
This is not to say that cell fusion may be universally beneficial to 
all cancers. First, syncytins may have additional effects within 
the tumour environment [46,47]. Second, it seems likely that 
several factors within the cancer and its stroma (e.g., 
inactivated tumour suppressor genes, activated oncogenes and 
expression of fusogens and of CD9, CD81 and TGF beta) may 
function together to bring about a tumour profile as diverse as 
that demonstrated by the cell fusion experiments referenced 
above. Expression of CD9 has been analysed in a number of 
tumours and seems, like syncytin expression, to correlate with a 
good prognosis [48–50]. 
 
Syncytin and endometrial carcinoma 
The vast majority of endometrial carcinomas express the 
oestrogen and progesterone receptors and are thought to 
develop from endometrial hyperplasia induced by steroid 
hormone stimulation. Strick et al [47] demonstrated that 
syncytin-1 expression is regulated via an oestrogen response 
element in these steroid-driven tumours, resulting in increased 
proliferation of primary endometrial carcinoma cells and cell 
lines. It is noteworthy that activation of cAMP signalling by 
forskolin or SP-cAMP also resulted in syncytin-1 gene up-
regulation, although this intervention led to increased cell–cell 
fusion instead of proliferation. Furthermore, they showed that, 
after stimulation with steroids or cAMP activation, syncytin-1 
gene is involved in anchorage-independent colony growth and 
fusion. The switch between cell proliferation and cell-–cell fusion 
was shown to be subject to a complex regulatory mechanism 
involving both steroid hormone- and TGF-β1/TGF-β3-dependent 
effects. The authors' findings raise the possibility that syncytins 
play an important role in the progression of hormone-dependent 
cancers, such as endometrial carcinoma. In healthy individuals, 
syncytin-1 protein expression is usually restricted to the 
placenta, and it has been suggested that CpG hypomethylation 
of the 5’ LTRs of both syncytin genes is one of the underlying 
regulatory mechanisms [51]. CpG hypomethylation also 
appears to be a means of activating syncytin-1 protein 
expression in ovarian carcinoma [52]. 
Since syncytin is up=regulated in endometrial carcinoma, the 
results of Strick et al [47] suggest that syncytin-1-mediated cell 
fusion may promote rather than suppress tumour growth. They 
demonstrated that syncytin-1 expression and function are highly 
dependent on hormonal regulation: steroid hormones such as 
estradiol (E2) induce the expression of syncytin-1 protein and 
result in increased cell proliferation and anchorage-independent 
growth. On the other hand, activation of cAMP signalling 
promotes both endometrial carcinoma cell fusion and 
anchorage-independent growth. Cell fusion can be blocked by 
TGF-β1/3, which is itself subject to steroid hormone regulation. 
Thus, in the presence of steroid hormones, TGF-β provides a 
switch between syncytin-1-mediated cell fusion and cell 
proliferation. Oestrogen is a key aetiological factor in 
endometrial carcinogenesis. Regulation by TGF-β and the 
involvement of syncytin-1 add a new dimension to our 
understanding of endometrial carcinoma progression. These 
findings reveal potential new directions for therapeutic 
approaches that circumvent the need for potentially risky 
endocrinological interventions. 
The identification of syncytin as a target of TGF-β in endometrial 
carcinoma not only provides novel insight into the molecular 
mechanisms of tumour progression but may also have 
important clinical implications. A peptide capable of inhibiting 
syncytin-mediated cell–cell fusion was recently shown to reduce 
breast carcinoma cell fusion with human umbilical vein 
endothelial cells by 50% (p<0.001) [45]. While this inhibitor has 
been tested only in an experimental setting and its toxicity 
profile has not yet been evaluated, the use of this peptide or of 
related reagents may have beneficial effects in the treatment of 
endometrial and, possibly, other carcinomas. However, there is 
a need to evaluate the contribution of cell fusion to the 
malignant phenotype of endometrial carcinoma cells to rule out 
the possibility that expression of syncytin is a mere 
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physiological response of the host to the tumour. Such a 
response could, for example, be aimed at neutralizing malignant 
cells via fusion with normal cells expressing tumour suppressor 
genes [53]. 
 
Syncytin and breast cancer 
Two series of human breast cancer patients were evaluated for 
tumoural expression of syncytin-1, using a polyclonal antiserum 
raised against a synthetic nanopeptide derived from the 
syncytin-1 sequence. In addition, tumours were also screened 
for expression of ASCT-2 using a peptide antiserum. Pre-
absorption of the antisera with the corresponding peptides, but 
not with irrelevant peptides, abolished staining [54]. 
The results show that 38% of all breast cancer samples 
displayed detectable staining for syncytin and that endothelial 
cells expressed ASCT-2. Moreover, significant expression of 
ASCT-2 was detected in many tumour cells. The degree of 
syncytin immunostaining was visually graded using coded 
specimens and statistical analysis showed that it correlated 
positively with the disease-free survival of patients [47]. 
Multivariate analysis included age dichotomised at 40 years, 
tumour size dichotomised at 20 mm, grade and adjuvant 
therapy, and it identified syncytin expression as an independent 
prognostic indicator of increased disease-free survival. When
used as a continuous variable, syncytin expression emerged as 
a significant prognostic indicator of disease-free survival in the 
Cox model (p = 0.02) [47]. 
 
Conclusions 
We believe that syncytins may be important fusogens for both 
trophoblast and cancer cell fusion, and that they may mediate 
additional cell fusion events, acting in concert with other 
molecules that have both enhancing and inhibitory regulatory 
effects. Both effects are relevant in mammalian 
placentogenesis. Syncytins have also been implicated in amino 
acid transport [28], immune tolerance [38] and protection 
against retroviral infections [41]. These functions of syncytin 
could all be utilized by cancers to gain a growth advantage, and, 
in our opinion, these functions should be studied in neoplasias. 
Correlations of syncytin with clinical parameters are scarce, but 
the most relevant data have been reported in breast cancer 
[53]. Besides laboratory approaches and clinical studies 
correlating syncytin-1 expression in endometrial carcinoma, 
breast carcinoma and other tumours, we believe that syncytin 
should be studied in relation to histopathological and 
clinicopathological parameters in order to assess the relevance 
of this potential novel molecular target. Its unique localization 
and distribution make syncytin attractive for the development of 
targeted therapies and immune therapies.  
 6  www.ecancermedicalscience.com 
R
e
v
i
e
w
s
 ecancer 2009, 3:145 
 
References 
1.  Kidwell MG and Lisch D (1997) Transposable elements 
as sources of variation in animals and plants Proc Natl 
Acad Sci USA 94 7704–11 PMID: 9223252 doi: 10.1073/ 
pnas.94.15.7704 
2.  McDonald JF (1993) Evolution and consequences of 
transposable elements  Curr Opin Genet Dev 3  855–64 
PMID: 8118210 doi: 10.1016/0959-437X(93)90005-A 
3.  Nekrutenko A and Li WH (2001) Transposable elements 
are found in a large number of human protein-coding 
genes  Trends Genet 17  619–21  PMID: 11672845  doi: 
10.1016/S0168-9525(01)02445-3 
4.  Lorenc A and Makalowski W (2003) Transposable 
elements and vertebrate protein diversity Genetica 118 
183–91 PMID: 12868608 doi: 10.1023/A:1024105726123 
5.  Sorek RR, Ast G and Graur D (2002) Alu-containing 
exons are alternatively spliced Genome Res 12 1060–7 
PMID: 12097342 doi: 10.1101/gr.229302 
6.  Britten RJ (2004) Coding sequences of functioning 
human genes derived entirely from mobile element 
sequences Proc Natl Acad Sci USA 101 16825–30 PMID 
15546984 10.1073/pnas.0406985101 
7.  Smit AF (1999) Interspersed repeats and other 
mementos of transposable elements in mammalian 
genomes Curr Opin Genet Dev 9 657–63 PMID: 10607616 
doi: 10.1016/S0959-437X(99)00031-3 
8.  Cohen M, Powers M, O'Connell C, and Kato N (1985) The 
nucleotide sequence of the env gene from the human 
provirus ERV3 and isolation and characterization of an 
ERV3-specific cDNA Virology 147 449–58 PMID: 3840930 
doi: 10.1016/0042-6822(85)90147-3 
9.  Blaise S, de Parseval N and Heidmann T (2005) 
Functional characterization of two newly identified 
human endogenous retrovirus coding envelope genes 
Retrovirology  2  19  PMID: 15766379  doi: 10.1186/1742-
4690-2-19 
10.  Blond JL, Beseme F and Duret L (1999) Molecular 
characterization and placental expression of HERV-W, 
a new human endogenous retrovirus family J Virol 73 
1175–85 PMID: 9882319 
11.  Mi S, Lee X, Li X et al (2000) Syncytin is a captive 
retroviral envelope protein involved in human placental 
morphogenesis Nature 403 785–9 PMID: 10693809 doi: 
10.1038/35001608 
12.  Blond JL, Lavillette D, Cheynet V et al (2000) An envelope 
glycoprotein of the human endogenous retrovirus 
HERV-W is expressed in the human placenta and fuses 
cells expressing the type D mammalian retrovirus 
receptor J Virol 74 3321–9 PMID: 10708449 doi: 10.1128/ 
JVI.74.7.3321-3329.2000 
13.  Frendo JL, Olivier D and Cheynet V (2003) Direct 
involvement of HERV-W Env glycoprotein in human 
trophoblast cell fusion and differentiation Mol Cell Biol 
23  3566–74  PMID: 12724415  doi:  10.1128/MCB.23.10. 
3566-3574.2003 
14.  Mallet F, Bouton O, Prudhomme S et al (2004) The 
endogenous retroviral locus ERVWE1 is a bona fide 
gene involved in hominoid placental physiology  Proc 
Natl Acad Sci USA 101  1731–6  PMID: 14757826  doi:  
10.1073/pnas.0305763101 
15.  Bonnaud B, Bouton O, Oriol G et al (2004) Evidence of 
selection on the domesticated ERVWE1 env retroviral 
element involved in placentation Mol Biol Evol 21 1895–
901 PMID: 15254254 doi:  10.1093/molbev/msh206 
16.  Voisset C, Blancher A, Perron H et al (1999) Phylogeny of 
a novel family of human endogenous retrovirus 
sequences, HERV-W, in humans and other primates 
AIDS Res Hum Retroviruses 15 1529–33 PMID: 10580403 
doi: 10.1089/088922299309810 
17.  Kim HS, Takenaka O and Crow TJ (1999) Isolation and 
phylogeny of endogenous retrovirus sequences 
belonging to the HERV-W family in primates J Gen Virol 
80 2613–9 PMID: 10573154 
18.  Caceres M (2006) Thomas The Gene of Retroviral Origin 
Syncytin 1 is Specific to Hominoids and is Inactive in 
Old World Monkeys J Heredity 97 100–6 PMID: 16424151 
doi: 10.1093/jhered/esj011 
19.  Blaise S, de Parseval N, Bénit L and Heidmann T (2003) 
Genome-wide screening for fusogenic human 
endogenous retrovirus envelopes identifies syncytin 2, 
a gene conserved on primate evolution Proc Natl Acad 
Sci USA 100  13013–8  PMID 14557543  10.1073/pnas. 
2132646100 
20.  Blaise S, Ruggieri A, Dewannieux M, Cosset F-L and 
Heidmann T (2004) Identification of an envelope protein 
from the FRD family of Human Endogenous 
Retroviruses (HERV-FRD) conferring infectivity and 
functional conservation among simians J Virol 78 1050–
4 PMID: 14694139 doi: 10.1128/JVI.78.2.1050-1054.2004 
21.  Colman PM and Lawrence MC (2003) The structural 
biology of type I viral membrane fusion Nat Rev Mol Cell 
Biol 4 309–19 PMID 12671653  10.1038/nrm1076 
22.  Bullough PA, Hughson FM, Skehel JJ and Wildley DC 
(1994) Structure of influenza hemagglutinin at the pH of 
membrane fusion Nature 371 37–43 PMID: 8072525 doi: 
10.1038/371037a0 
23.  Chen J, Skehel JJ and Wiley DC (1999) N- and C-terminal 
residues combine in the fusion-Ph influenza 
 7  www.ecancermedicalscience.com 
R
e
v
i
e
w
s
 ecancer 2009, 3:145 
 
hemagglutinin HA2 subunit to form an N CAP that 
terminates the triple-stranded coiled coil Proc Natl Acad 
Sci USA 96 8967–73 PMID: 10430879 doi: 10.1073/pnas. 
96.16.8967 
24.  Renard M, Varela PF, Letzelterl C, Duquerroy D, Rey F and 
Heidmann T (2005) Crystal structure of a pivotal domain 
of human syncytin-2, a 40 million years old 
endogenous retrovirus fusogenic envelope gene 
captured by primates  J Mol Biol 352  1029–34  PMID: 
16140326 doi: 10.1016/j.jmb.2005.07.058 
25.  Stoye JP and Coffn JM (2000) A provirus put to work 
Nature  403  715–7  PMID: 10693785  doi:  10.1038/ 
35001700 
26.  Frendo J-L, Olivier D, Cheynet V et al (2003) Direct 
involvement of HERV-W Env glycoprotein in human 
trophoblast cell fusion and differentiation Mol Cell Biol 
23  3566–74  PMID: 12724415  doi:  10.1128/MCB.23.10. 
3566-3574.2003 
27.  Okulitz WC and Ace CI (2003) Temporal regulation of 
gene expression during the expected window of 
receptivity in the rhesus monkey endometrium  Biol 
Reprod  69  1593–9  PMID: 12855598  doi:  10.1095/ 
biolreprod.103.017525 
28.  Nelson DM, Smith SD, Furesz TC, Sadovsky Y, Ganapathy 
V, Parvin CA and Smith CH (2003) Hypoxia reduces 
expression and function of system A amino acid 
transporters in cultured term human trophoblasts Am J 
Physiol Cell Physiol 284 C310–5 PMID: 12388062 
29.  Moe AJ (1995) Placental amino acid transport  Am J 
Physiol 268 C1321–31 PMID: 7611349 
30.  Kudo Y and Boyd C (2002) Changes in expression and 
function of syncytin and its receptor, amino acid 
transport system B (0) (ASCT2), in human placental 
choriocarcinoma BeWo cells during syncytialization 
Placenta  23 536–41 PMID: 12175968  doi: 10.1053/plac. 
2002.0839 
31.  Furesz C, Smith CH and Moe AJ (1993) ASC system 
activity is altered by development of cell polarity in 
trophoblast from human placenta  Am J Physiol 265 
C212–7 PMID: 8338132 
32.  Tailor CS, Nouri A, Zhao Y, Takeuchi Y and Kabat D (1999) 
A sodium-dependent neutral-amino-acid transporter 
mediates infections of feline and baboon endogenous r 
etroviruses and simian type D retroviruses J Virol 73 
4470–4 PMID: 10196349 
33.  Rasko JE, Battini JL, Gottschalk RJ, Mazo I and Miller AD 
(1999) The RD114/simian type D retrovirus receptor is a 
neutral amino acid transporter Proc Natl Acad Sci USA 
96 2129–34 PMID: 10051606 doi:  10.1073/pnas.96.5.2129 
34.  Norberg S, Powell TL and Jansson T (1998) Intrauterine 
growth restriction is associated with a reduced activity 
of placental taurine transporters Pediatr Res 44 233–8 
PMID: 9702920 doi: 10.1203/00006450-199808000-00016 
35.  Glazier J, Cetin I, Perugino G, Ronzoni S, Grey AM, 
Mahendran D, Marconi AM, Pardi G and Sibley C (1997) 
Association between the activity of the system A amino 
acid transporter in the microvillous plasma membrane 
of the human placenta and severity of fetal 
compromise in intrauterine growth restriction  Pediatr 
Res  42  514–9  PMID: 9380446  doi: 10.1203/00006450-
199710000-00016 
36.  Harrington B, Glazier J, D'Souza S and Sibley C (1999) 
System A amino acid transporter activity in human 
placental microvillous membrane vesicles in relation to 
various anthropometric measurements in appropriate 
and small for gestational age babies  Pediatr Res 45 
810–4  PMID: 10367770  doi:  10.1203/00006450-
199906000-00005 
37.  Speake PF, Glazier J, Ayuk PTY, Reade M, Sibley C and 
D'Souza S (2003) L-Arginine transport across the basal 
plasma membrane of the syncytiotrophoblast of the 
human placenta from normal and preeclamptic 
pregnancies J Clin Endocrinol Metab 88 4287–92 PMID: 
12970300 doi: 10.1210/jc.2003-030067 
38.  Cianciolo GJ, Copeland TD, Oroszlan S and Snyderman R 
(1985)  Inhibition of lymphocyte proliferation by a 
synthetic peptide homologous to retroviral envelope 
proteins Science 230 453–5 PMID: 2996136 doi:  10.1126/ 
science.2996136 
39.  Blaschitz A, Hutter H and Dohr G (2001) HLA Class I 
protein expression in the human placenta  Early 
Pregnancy 5 67–9 PMID 11753519 
40.  Bennett WA, Lagoo-Deenadayalan S, Whitworth NS et al 
(1999)  First-trimester human chorionic villi express 
both immunoregulatory and inflammatory cytokines: a 
role for interleukin-10 in regulating the cytokine 
network of pregnancy  Am J Reprod Immunol 41  70–8 
PMID: 10097789 
41.  Ponferrada VG, Mauck BS and Wooley DP (2003) The 
envelope glycoprotein of human endogenous 
retrovirus HERV-W induces cellular resistance to 
spleen necrosis virus Arch Virol 148  659–75  PMID: 
12664292 doi: 10.1007/s00705-002-0960-x 
42.  Cheng YH, Richardson BD, Hubert MA and Handwerger S 
(2004)  Isolation and Characterization of the Human 
Syncytin Gene Promoter Biol Reprod 70 694–701 PMID: 
14613893 doi: 10.1095/biolreprod.103.023473 
43.  Cheng YH and Handwerger S (2005) A placenta-specific 
enhancer of the human syncytin gene  Biol Reprod 73 
 8  www.ecancermedicalscience.com 
R
e
v
i
e
w
s
 ecancer 2009, 3:145 
 
500–9  PMID: 15888734  doi: 10.1095/biolreprod.105. 
039941 
44.  Mortensen K, Lichtenberg J, Thomsen PD and Larsson LI 
(2004)  Spontaneous fusion between cancer cells and 
endothelial cells  Cell Mol Life Sci 61  2125–31  PMID: 
15316661 doi: 10.1007/s00018-004-4200-2 
45.  Bjerregaard B, Holck S, Christensen IJ and Larsson LI 
(2006) Syncytin is involved in breast cancer-endothelial 
cell fusions Cell Mol Life Sci 63 1906–11 PMID: 16871371 
doi: 10.1007/s00018-006-6201-9 
46.  Larsson JI, Bjerregaard B and Talts JF (2008) Cell fusions 
in mammals Histochem Cell Biol  129  551–61  PMID: 
18351375 doi:10.1007/s00418-008-0411-1 
47.  Strick R, Ackermann S, Langbein M et al (2007) 
Proliferation and cell–cell fusion of endometrial 
carcinoma are induced by the human endogenous 
retroviral syncytin-1 and regulated by TGF-beta J Mol 
Med 85 23–38 PMID 17066266 10.1007/s00109-006-0104-
y 
48.  Uchida S, Shimada Y, Watanabe G, Li ZG, Hong T, Miyake 
M and Imamura M (1999) Motility-related protein (MRP-
1/CD9) and KAI1/ CD82 expression inversely correlate 
with lymph node metastasis in oesophageal squamous 
cell carcinoma Br J Cancer 79 1168–73 PMID: 10098753 
doi:10.1038/sj.bjc.6690186 
49.  Hashida H, Takabayashi A, Tokuhara T et al (2002) 
Integrin alpha3 expression as a prognostic factor in 
colon cancer:association with MRP-1/CD9 and 
KAI1/CD82 Int J Cancer 97 518–25 PMID: 11802216 doi:  
10.1002/ijc.1625 
50.  Funakoshi T, Tachibana I, Hoshida Y et al (2003) 
Expression of tetraspanins in human lung cancer 
cells:frequent downregulation of CD9 and its 
contribution to cell motility in small cell lung cancer 
Oncogene  22  674–87  PMID: 12569360  doi:10.1038/ 
sj.onc.1206106 
51.  Matouskova M, Blazkova J, Pajer P, Pavlicek A and Hejnar 
J (2006) CpG methylation suppresses transcriptional 
activity of human syncytin-1 in non-placental tissues 
Exp Cell Res 312 1011–20 PMID: 16427621 doi: 10.1016/ 
j.yexcr.2005.12.010 
52.  Menendez L, Benigno BB and McDonald JF (2004) L1 and 
HERV-W retrotransposons are hypomethylated in 
human ovarian carcinomas  Mol Cancer 3  12  PMID: 
15109395 doi: 10.1186/1476-4598-3-12 
53.  Ogle BM, Cascalho M and Platt JL (2005) Biological 
implications of cell fusion Nat Rev Mol Cell Biol 6 567–
75 PMID: 15957005 doi: 10.1038/nrm1678 
54.  Larsson LI, Holck S and Christensen IJ (2007) Prognostic 
role of syncytin expression in breast cancer Hum Pathol 
38 726–31 PMID 17306327 doi: 10.1016/j.humpath.2006. 
10.018  
 9  www.ecancermedicalscience.com 
R
e
v
i
e
w
s
 